BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

ALKERMES PHARMACEUTICALS CORPORATION — Receipts Report

LD-2 disclosure · 4th Quarter - Amendment

ALKERMES PHARMACEUTICALS CORPORATION

via ARTEMIS STRATEGIES

4th Quarter (Oct 1 - Dec 31) · 2016Posted Mar 9, 2017Filing document ↗LDA record ↗

Income$30Kfee reported

Client

Name: ALKERMES PHARMACEUTICALS CORPORATION
Description: Pharmaceuticals development and manufacturing
Location: Massachusetts · United States of America

Registrant

Firm: ARTEMIS STRATEGIES
Description: consultant
Location: Waterford, Virginia, United States of America

Lobbying activities

1 issue

Pharmacy
The Comprehensive Addiction and Recovery Act, S. 524 and H.R. 953
Lobbyistsmr TIMOTHY F POWERS
TargetedSENATE · HOUSE OF REPRESENTATIVES

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.